International archives of allergy and immunology · 2025
Comparative Efficacy of Montelukast-Levocetirizine Combination Therapy versus Monotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Ji-Sun, Stybayeva Gulnaz, Hwang Se Hwan
Аннотация
UNLABELLED: <p>Introduction: Combination therapy with antihistamines and leukotriene receptor antagonists (LTRAs) is frequently used in allergic rhinitis (AR), particularly in patients with persistent or inadequately controlled symptoms. However, supporting evidence has been inconsistent. This meta-analysis assessed the efficacy of montelukast combined with levocetirizine in patients with AR by directly comparing the combination therapy with each monotherapy and evaluating individual symptom domains.
METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted, with database searches performed through March 2025. Outcomes included daytime and nighttime total symptom scores, individual nasal symptoms, rhinoconjunctivitis-related quality of life (RQLQ), and treatment-emergent adverse events (TEAEs). Pooled effects were calculated using standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs).
RESULTS: Seven RCTs (n = 887) were included. Combination therapy resulted in greater improvement in daytime symptoms (SMD [95% CI]: -0.42 [-0.64 to -0.20]), rhinorrhea (SMD [95% CI]: -0.69 [-1.09 to -0.30]), and nasal congestion (SMD [95% CI]: -0.64 [-1.05 to -0.24]) compared to monotherapy. RQLQ scores improved modestly overall (SMD [95% CI]: -0.37 [-0.72 to -0.01]), but subgroup analyses showed no significant difference compared to individual agents. TEAE rates were similar across groups (OR [95% CI]: 1.05 [0.57 to 1.94]).
CONCLUSION: Montelukast-levocetirizine combination therapy provided superior symptom control without increased adverse events, supporting its use as a potential treatment option in selected patients with AR. </p>.
METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted, with database searches performed through March 2025. Outcomes included daytime and nighttime total symptom scores, individual nasal symptoms, rhinoconjunctivitis-related quality of life (RQLQ), and treatment-emergent adverse events (TEAEs). Pooled effects were calculated using standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs).
RESULTS: Seven RCTs (n = 887) were included. Combination therapy resulted in greater improvement in daytime symptoms (SMD [95% CI]: -0.42 [-0.64 to -0.20]), rhinorrhea (SMD [95% CI]: -0.69 [-1.09 to -0.30]), and nasal congestion (SMD [95% CI]: -0.64 [-1.05 to -0.24]) compared to monotherapy. RQLQ scores improved modestly overall (SMD [95% CI]: -0.37 [-0.72 to -0.01]), but subgroup analyses showed no significant difference compared to individual agents. TEAE rates were similar across groups (OR [95% CI]: 1.05 [0.57 to 1.94]).
CONCLUSION: Montelukast-levocetirizine combination therapy provided superior symptom control without increased adverse events, supporting its use as a potential treatment option in selected patients with AR. </p>.